Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 12/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338741 | 1.00 | RIPK1 (0.49) | RIPK1TP53PANK3CTSSGSK3B | |
| SCHEMBL25253169 | 0.92 | RIPK1 (0.50) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL30339063 | 0.92 | RIPK1 (0.50) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL30338933 | 0.90 | RIPK1 (0.49) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL25256162 | 0.90 | RIPK1 (0.49) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL25817088 | 0.90 | RIPK1 (0.46) | RIPK1PANK3CTSSKDM4E | |
| SCHEMBL30338915 | 0.90 | RIPK1 (0.46) | RIPK1PANK3CTSSKDM4E | |
| SCHEMBL25250096 | 0.90 | RIPK1 (0.49) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL30338864 | 0.90 | RIPK1 (0.49) | RIPK1TP53GSK3BDYRK1ATHRB | |
| SCHEMBL25816909 | 0.90 | RIPK1 (0.51) | RIPK1PANK3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | claimed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885TP53 4639/4885PANK3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.